New drugs to overcome meccanisms of resistance in Ph+ leukemia: Bosutinib

Haematologica Meeting Reports

Volumn 2, Issue 5, 2008, Pages 27-32

  Martinelli, G ^a   Iacobucci, I ^a   Cilloni, D ^b   Giannoulia, P ^a   Soverini, S ^a   Piccaluga, P P ^a   Papayannidis, C ^a   Paolini, S ^a   Terragna, C ^a   Amabile, M ^a   Colarossi, S ^a   Gnani, A ^a   Pane, F ^c   Saglio, G ^b   Baccarani, M ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOCYTIC LEUKEMIA; AMINO ACID SUBSTITUTION; ANEMIA; BILIRUBIN BLOOD LEVEL; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER RISK; CHROMOSOME; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOGENETICS; DIARRHEA; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEMATOPOIETIC STEM CELL; HUMAN; NAUSEA; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; PHILADELPHIA CHROMOSOME POSITIVE CELL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SIDE EFFECT; THROMBOCYTOPENIA; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; VOMITING;

EID: 54249140433     PISSN: 19707339     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (28)

1. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109. No abstract available.
2. Rowley JD. Letter: Deletions of chromosome 7 in haematological disorders. Lancet. 1973 Dec 15;2:1385-6. No abstract available.
3. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9.
4. Chan LC, Chen PM, Powles R, Saragas E, Wiedemann LM, Groffen J, Greaves MF. Molecular lesion in chronic granulocytic leukemia is highly conserved despite ethnic and geographical variation. Leukemia 1987;1:486-90.
5. Clark SS, McLaughlin J, Crist WM, Champlin R, Witte ON. Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. Science 1987;235:85-8.
6. Wong S, Witte ON. The BCR-ABL story: bench to bed-side and back. Annu Rev Immunol 2004;22:247-306. Review.
7. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood. 2004 Jun 1;103(11):4010-22. Epub 2004 Feb 24. Review.
8. Aricò M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. New Engl J Med 2000;342:998-1006.
9. Gleissner B, Gökbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 2002;99:1536-43.
10. Deininger MW. Management of early stage disease. Hematology Am Soc Hematol Educ Program 2005:174-82.
11. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. European LeukemiaNet. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809-20. Epub 2006 May 18. Review.
12. Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, et al. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood 2006;107:4250-6. Epub 2006 Feb 7.
13. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. GIMEMA Working Party on Chronic Myeloid Leukemia. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12:7374-9.
14. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
15. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.
16. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
17. Hochhaus A. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. Expert Opin Pharmacother 2007;8:3257-64. Review.
18. Bruemmendorf TH, Cervantes F, Kim D, Chandy M, Fischer T, Hochhaus A, et al. Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors. J Clin Oncol 2008:26 (May 20 suppl; abstr 7001)
19. Vitale A, Guarini A, Ariola C, Mancini M, Mecucci C, Cuneo A, et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006;107:473-9. Epub 2005 Sep 22.
20. Deininger MW. Nilotinib. Clin Cancer Res 2008 Jul 1;14:4027-31.
21. + ALL. J Clin Oncol 26: 2008 (May 20 suppl; abstr 7049.
22. Konig H, Holyoake TL, Bhatia R. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606. Blood 2008;111:2329-38.
23. Quintás-Cardama A, Cortes J. Tailoring tyrosine kinase inhibitor therapy to tackle specific BCR-ABL1 mutant clones. Leuk Res 2008;32:1313-6. Epub 2008 Feb 1.
24. Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003:15;63:375-81.
25. Boschelli DH, Wu B, Barrios Sosa AC, Durutlic H, Chen JJ, Wang Y, et al. Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles. J Med Chem 2005;48:3891-902.
26. Golas JM, Lucas J, Etienne C, Golas J, Discafani C, Sridharan L, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005;65:5358-64.
27. Berger DM, Dutia M, Birnberg G, Powell D, Boschelli DH, Wang YD, et al. 4-Anilino-7,8-dialkoxybenzo [g]quinoline-3-carbonitriles as potent Src kinase inhibitors. J Med Chem 2005;48:5909-20.
28. Puttini M, Coluccia AM, Boschelli F, Cleris L, Marchesi E, Donella- Deana, Aet al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006;66:11314-22. Epub 2006 Nov 17.